Baidu
map

Int J GynecolCancer:阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验

2017-06-23 孙恒子 彭澎 教授 协和妇产科文献月报

研究背景:有证据表明,一部分复发性卵巢癌患者能够受益于抗雌激素治疗。Paragon试验包括一系列评价阿那曲唑在雌激素受体或孕激素受体阳性的复发性妇科肿瘤患者中治疗效果的研究。本文报道阿那曲唑在雌激素受体或孕激素受体阳性的、铂类耐药的、复发性卵巢上皮癌患者中的治疗效果。研究方法:选取雌激素受体或孕激素受体阳性且铂类耐药的复发性卵巢上皮癌患者入组并应用实体瘤治疗疗效评价标准(Response Eval

研究背景:有证据表明,一部分复发性卵巢癌患者能够受益于抗雌激素治疗。Paragon试验包括一系列评价阿那曲唑在雌激素受体或孕激素受体阳性的复发性妇科肿瘤患者中治疗效果的研究。本文报道阿那曲唑在雌激素受体或孕激素受体阳性的、铂类耐药的、复发性卵巢上皮癌患者中的治疗效果。

研究方法:选取雌激素受体或孕激素受体阳性且铂类耐药的复发性卵巢上皮癌患者入组并应用实体瘤治疗疗效评价标准(Response Evaluation Criteria InSolid Tumors,RECIST1.1版)或妇科肿瘤国际小组(Gynecologic Cancer InterGroup, GCIG)CA125标准评估患者临床疗效,临床受益包括3个月内病情完全或部分缓解或病情稳定。入组患者接受每天1mg阿那曲唑的治疗,持续用药直到疾病进展或出现不可耐受的毒性反应。本研究进行了前瞻性的注册(ACTRN12610000796088)。

研究结果:本研究共入组49例患者,其中有13例(27%,95%CI 16%-40%)患者收到临床获益,无患者达到RECIST标准的完全或部分缓解。临床获益与患者更高的生活质量评分相关。患者无进展中位生存时间为2.7个月(95% CI, 2.0-2.8个月)。临床获益中位持续时间为2.8个月(95% CI, 2.6-5.7个月)。83%的患者6个月内病情进展,7例患者持续治疗时间超过6个月。阿那曲唑在大多数患者中耐受性良好。亚组分析表明肿瘤雌激素受体Histoscore评分超过200的患者能够获得更好的临床疗效,但差异无统计学意义。

研究结论:一部分雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者能够在阿那曲唑的治疗中获益且毒副反应耐受性好,然而目前的挑战依然是无有效方法将这部分患者筛查出来。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Feb 13 21:30:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737520, encodeId=0ed71e37520f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Nov 18 14:30:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat May 05 11:30:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 08 01:30:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043973, encodeId=26c220439e3f4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 13 06:30:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909639, encodeId=662819096397e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 14 04:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215867, encodeId=2da821586e63, content=新的治疗方法,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Tue Jun 27 07:53:51 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215380, encodeId=18142153803d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jun 25 23:54:12 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385354, encodeId=90731385354de, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Feb 13 21:30:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737520, encodeId=0ed71e37520f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Nov 18 14:30:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat May 05 11:30:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 08 01:30:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043973, encodeId=26c220439e3f4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 13 06:30:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909639, encodeId=662819096397e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 14 04:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215867, encodeId=2da821586e63, content=新的治疗方法,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Tue Jun 27 07:53:51 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215380, encodeId=18142153803d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jun 25 23:54:12 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385354, encodeId=90731385354de, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Feb 13 21:30:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737520, encodeId=0ed71e37520f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Nov 18 14:30:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat May 05 11:30:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 08 01:30:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043973, encodeId=26c220439e3f4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 13 06:30:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909639, encodeId=662819096397e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 14 04:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215867, encodeId=2da821586e63, content=新的治疗方法,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Tue Jun 27 07:53:51 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215380, encodeId=18142153803d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jun 25 23:54:12 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385354, encodeId=90731385354de, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Feb 13 21:30:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737520, encodeId=0ed71e37520f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Nov 18 14:30:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat May 05 11:30:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 08 01:30:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043973, encodeId=26c220439e3f4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 13 06:30:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909639, encodeId=662819096397e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 14 04:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215867, encodeId=2da821586e63, content=新的治疗方法,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Tue Jun 27 07:53:51 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215380, encodeId=18142153803d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jun 25 23:54:12 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385354, encodeId=90731385354de, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Feb 13 21:30:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737520, encodeId=0ed71e37520f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Nov 18 14:30:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat May 05 11:30:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 08 01:30:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043973, encodeId=26c220439e3f4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 13 06:30:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909639, encodeId=662819096397e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 14 04:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215867, encodeId=2da821586e63, content=新的治疗方法,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Tue Jun 27 07:53:51 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215380, encodeId=18142153803d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jun 25 23:54:12 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385354, encodeId=90731385354de, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Feb 13 21:30:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737520, encodeId=0ed71e37520f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Nov 18 14:30:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat May 05 11:30:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 08 01:30:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043973, encodeId=26c220439e3f4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 13 06:30:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909639, encodeId=662819096397e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 14 04:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215867, encodeId=2da821586e63, content=新的治疗方法,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Tue Jun 27 07:53:51 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215380, encodeId=18142153803d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jun 25 23:54:12 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385354, encodeId=90731385354de, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Feb 13 21:30:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737520, encodeId=0ed71e37520f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Nov 18 14:30:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat May 05 11:30:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 08 01:30:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043973, encodeId=26c220439e3f4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 13 06:30:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909639, encodeId=662819096397e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 14 04:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215867, encodeId=2da821586e63, content=新的治疗方法,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Tue Jun 27 07:53:51 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215380, encodeId=18142153803d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jun 25 23:54:12 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385354, encodeId=90731385354de, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=)]
    2017-06-27 日月生辉

    新的治疗方法,学习了!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Feb 13 21:30:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737520, encodeId=0ed71e37520f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Nov 18 14:30:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat May 05 11:30:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 08 01:30:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043973, encodeId=26c220439e3f4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 13 06:30:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909639, encodeId=662819096397e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 14 04:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215867, encodeId=2da821586e63, content=新的治疗方法,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Tue Jun 27 07:53:51 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215380, encodeId=18142153803d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jun 25 23:54:12 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385354, encodeId=90731385354de, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=)]
    2017-06-25 luominglian113

    学习了,谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Feb 13 21:30:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737520, encodeId=0ed71e37520f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Nov 18 14:30:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat May 05 11:30:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 08 01:30:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043973, encodeId=26c220439e3f4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 13 06:30:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909639, encodeId=662819096397e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 14 04:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215867, encodeId=2da821586e63, content=新的治疗方法,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Tue Jun 27 07:53:51 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215380, encodeId=18142153803d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jun 25 23:54:12 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385354, encodeId=90731385354de, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1980840, encodeId=4dc9198084077, content=<a href='/topic/show?id=aaf6668192d' target=_blank style='color:#2F92EE;'>#激素受体阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66819, encryptionId=aaf6668192d, topicName=激素受体阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue Feb 13 21:30:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737520, encodeId=0ed71e37520f1, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Sat Nov 18 14:30:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940394, encodeId=39961940394c8, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat May 05 11:30:00 CST 2018, time=2018-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96591, encryptionId=85df9659123, topicName=铂类耐药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 08 01:30:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043973, encodeId=26c220439e3f4, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 13 06:30:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909639, encodeId=662819096397e, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Mon Aug 14 04:30:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215867, encodeId=2da821586e63, content=新的治疗方法,学习了!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Tue Jun 27 07:53:51 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215380, encodeId=18142153803d, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jun 25 23:54:12 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1349605, encodeId=e4f01349605a8, content=<a href='/topic/show?id=b97d425286c' target=_blank style='color:#2F92EE;'>#复发性卵巢癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42528, encryptionId=b97d425286c, topicName=复发性卵巢癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385354, encodeId=90731385354de, content=<a href='/topic/show?id=9aeb45318ed' target=_blank style='color:#2F92EE;'>#孕激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45318, encryptionId=9aeb45318ed, topicName=孕激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=05a2499, createdName=dzx0922889, createdTime=Sun Jun 25 07:30:00 CST 2017, time=2017-06-25, status=1, ipAttribution=)]

相关资讯

Lancet:阿那曲唑 vs 他莫昔芬治疗对导管原位癌切除的绝经后女性生活质量的影响

NSABP B-35试验比较了用阿那曲唑与他莫昔芬治疗5年来减少绝经后导管原位癌患者后续发生乳腺癌的效果。该报告评估了这些药物对生活质量和症状的影响。

ESMO 2016:氟维司群可延长乳腺癌患者的无进展生存期(FALCON试验)

根据欧洲肿瘤医学学会大会上的3期研究结果:对于激素受体阳性的晚期乳腺癌女性患者而言,氟维司群与阿那曲唑相比,可显著延长患者的无进展生存期(PFS)。氟维司群是选择性雌激素受体的降解物,靶向激素受体的功能。与阿那曲唑等芳香酶抑制剂不同的是,它不会干扰雌激素的水平。来自贝勒医学院莱斯特和苏史密斯乳腺中心的Matthew J. Ellis博士和同事们纳入了462名ER阳性或PR阳性的局部晚期或转移性乳腺

Lancet:对于雌激素受体阳性的晚期乳腺癌患者氟维司群疗效比阿那曲唑更好

对于没有接受过内分泌治疗的激素受体阳性的局部晚期或转移性乳腺癌患者,相比于用于这些患者的一线治疗的标准治疗药物-第三代芳香化酶抑制剂,氟维司群具有优越的疗效并且可以作为这些患者的首选治疗药物。

阿斯利康抗癌药Faslodex(氟维司群)治疗HR+晚期乳腺癌疗效显著优于Arimidex(阿那曲唑)

英国制药巨头阿斯利康(AstraZeneca)近日公布了抗癌药Faslodex 500mg注射液(fulvestrant,氟维司群)一项乳腺癌III期临床研究(FALCON)的积极数据。该研究是一项随机、双盲、多中心III期研究,在既往未接受任何激素疗法治疗的激素受体阳性(HR+)局部晚期或转移性乳腺癌绝经后女性患者中开展,将Faslodex 500mg注射液与该公司的抗癌药Arimidex

Fertil Steril.:雄激素缺乏生育力低下男性接受阿那曲唑 结局有何改善?

2017年3月,发表在《Fertil Steril》的一项由美国科学家进行的研究考察了阿那曲唑在少精症雄激素缺乏生育力低下男性中的结局。

Fertil Steril:雄激素缺乏生育力低下男性接受阿那曲唑 结局有何改善?

2017年3月,发表在《Fertil Steril》的一项由美国科学家进行的研究考察了阿那曲唑在少精症雄激素缺乏生育力低下男性中的结局。

Baidu
map
Baidu
map
Baidu
map